NeuroSense Therapeutics

NRSN Rare disease Lead: Phase 2 ★ Read the deep dive → 6 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-31

Catalyst timeline

NRSN Nasdaq listing updateSep 29, 2026NRSN Nasdaq listing update, Sep 29, 2026, notable
PrimeC Ph3 startDec 2026PrimeC Ph3 start, Dec 2026, notable
PrimeC filingDec 2026PrimeC filing, Dec 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

PrimeC

ciprofloxacin · celecoxib · NST003

Small Molecule Target: TDP-43

Amyotrophic Lateral Sclerosis Phase 2 oral NCT04090684

PrimeC

ciprofloxacin · celecoxib

Small Molecule

Alzheimer's Disease Phase 2 oral NeuroKaire NCT06185543

StabiliC

ciprofloxacin · celecoxib

Small Molecule

Parkinson's Disease Preclinical oral

Biotech Distilled coverage (6)

2026-09-09 UPDATE: NeuroSense Therapeutics (NRSN) - The Ratio Is 1-for-20 🔒 Paid
2026-08-31 UPDATE: NeuroSense Therapeutics (NRSN) - PARAGON Gets Shrunk 🔒 Paid
2026-07-31 UPDATE: NeuroSense Therapeutics (NRSN) - The Reverse Split Goes on the Ballot
2026-07-30 UPDATE: NeuroSense Therapeutics (NRSN) - The Chasm Gets Papered
2026-07-22 UPDATE: NeuroSense Therapeutics (NRSN) - The Canada Card Gets Played
2026-07-11 NeuroSense Therapeutics (NRSN) — Scientific Deep Dive for PrimeC and Pipeline Products

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.